- Home
- EWTX vs MLKN Comparison
EWTX vs MLKN Comparison
Compare EWTX & MLKN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- MLKN
- Stock Information
- Founded
- EWTX 2017
- MLKN 1905
- Country
- EWTX United States
- MLKN United States
- Employees
- EWTX N/A
- MLKN N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- MLKN Office Equipment/Supplies/Services
- Sector
- EWTX Health Care
- MLKN Consumer Discretionary
- Exchange
- EWTX Nasdaq
- MLKN Nasdaq
- Market Cap
- EWTX 1.2B
- MLKN 1.0B
- IPO Year
- EWTX 2021
- MLKN N/A
- Fundamental
- Price
- EWTX $14.58
- MLKN $16.78
- Analyst Decision
- EWTX Buy
- MLKN
- Analyst Count
- EWTX 8
- MLKN 0
- Target Price
- EWTX $40.13
- MLKN N/A
- AVG Volume (30 Days)
- EWTX 1.2M
- MLKN 471.1K
- Earning Date
- EWTX 05-08-2025
- MLKN 06-25-2025
- Dividend Yield
- EWTX N/A
- MLKN 4.48%
- EPS Growth
- EWTX N/A
- MLKN N/A
- EPS
- EWTX N/A
- MLKN 0.43
- Revenue
- EWTX N/A
- MLKN $3,597,000,000.00
- Revenue This Year
- EWTX N/A
- MLKN $1.97
- Revenue Next Year
- EWTX N/A
- MLKN $3.05
- P/E Ratio
- EWTX N/A
- MLKN $39.33
- Revenue Growth
- EWTX N/A
- MLKN N/A
- 52 Week Low
- EWTX $10.60
- MLKN $15.25
- 52 Week High
- EWTX $38.12
- MLKN $31.73
- Technical
- Relative Strength Index (RSI)
- EWTX 41.67
- MLKN 48.68
- Support Level
- EWTX $13.82
- MLKN $15.77
- Resistance Level
- EWTX $17.30
- MLKN $16.78
- Average True Range (ATR)
- EWTX 1.02
- MLKN 0.53
- MACD
- EWTX 0.32
- MLKN 0.19
- Stochastic Oscillator
- EWTX 30.43
- MLKN 88.33
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About MLKN MillerKnoll Inc.
MillerKnoll Inc, formerly Herman Miller Inc researches, designs, manufactures, sells, and distributes interior furnishings across the globe. The Company has three reportable segments: Americas Contract , International Contract & Specialty International & Specialty and Global Retail. The company's products are sold through a variety of sources, including owned and independent contract furniture dealers, direct customer sales, owned and independent retailers, direct-mail catalogs, and the company's online stores. The independent retailer division generates the majority of the firm's overall sales.